Pilot Study of B-Type Natrieutic Peptide (BNP) Levels in Patients With Congenital Heart Disease(BNP)
A Pilot Study of B-Type Natriuretic Peptide (BNP) Levels in Patients With Congenital Heart Disease and Systemic Right Ventricles or Volume Overloaded Pulmonic Right Ventricles
1 other identifier
interventional
34
0 countries
N/A
Brief Summary
The object of this study is to measure the levels of B-type Natriuretic Peptide (BNP) in patients with congenital heart disease, normal individuals, and patients with acquired heart failure, and compare the results from each group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2001
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2001
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2004
CompletedFirst Submitted
Initial submission to the registry
March 27, 2006
CompletedFirst Posted
Study publicly available on registry
March 29, 2006
CompletedResults Posted
Study results publicly available
July 17, 2014
CompletedJuly 17, 2014
July 1, 2014
2.2 years
March 27, 2006
September 10, 2013
July 16, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
BNP Levels
Levels of B-type naturietic peptide in the blood
1 day
Study Arms (3)
Normal Heart
PLACEBO COMPARATORControl Group with Normal Heart
Congenital Heart Disease
ACTIVE COMPARATORTetralogy of Fallot, DTGA, CCTGA
Heart Failure
ACTIVE COMPARATORLeft ventricular heart failure, no congestive heart disease
Interventions
Eligibility Criteria
You may not qualify if:
- Single ventricle and or single atria Liver disease with portal hypertension Renal disease requiring dialysis Creatine \> 4.0 Significant pulmonary hypertension (systolic PAP \>60 mmHg by Echo) Uncontrolled systemic arterial hypertension (systolic \> 200 mmHg or diastolic \>105 mmHg) Myocardial infarction or acute coronary syndrome within 2 months D-TGA status post atrial switch procedure (Jatene) Intracardiac shunts Inadequate echocardiogram windows Coronary Angioplasty 30 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Emory Universitylead
- Pfizercollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Wendy Book
- Organization
- Emory University
Study Officials
- PRINCIPAL INVESTIGATOR
Wendy M Book, M.D.
Emory University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 27, 2006
First Posted
March 29, 2006
Study Start
December 1, 2001
Primary Completion
March 1, 2004
Study Completion
September 1, 2004
Last Updated
July 17, 2014
Results First Posted
July 17, 2014
Record last verified: 2014-07